While we have not pulled the trigger & bought C79 (yet), we continue to think it is one of the more compelling industrial technology names on the ASX, combining genuine IP, a recurring revenue model and direct leverage to activity levels across the gold industry. The company’s PhotonAssay technology is clearly solving a real problem for miners and labs. Faster turnaround, improved accuracy and a safer alternative to traditional fire assay, and the commercial traction now shows this is well beyond the “promising concept” phase.
- In its 1H FY26 results, Chrysos reported 49% revenue growth to $43.3m, highlighted 70–80% gross margins, and noted that total contracted units had expanded to 72, with a strengthened $200m syndicated facility to support further rollout.
As we all know, gold prices have been strong, and when the gold price is strong, exploration economics improve, lower-grade deposits become more viable, mine life extensions get more attention, and producers are generally more willing to spend money trying to define and expand resources.
S&P Global data supports the view, showing gold exploration budgets rose 11% to US$6.15bn, implying a good backdrop for PhotonAssay demand. That doesn’t mean the benefit is purely cyclical, because Chrysos is still winning share through technology adoption, but a stronger gold price should help broaden the runway. Encouragingly, S&P says exploration spend is increasingly concentrated around existing mines, rather than early-stage greenfields work. That suits Chrysos: mine-site and near-mine exploration work tends to be the sort of activity where faster turnaround times and operational efficiency matter most, and where PhotonAssay can become embedded in day-to-day workflows rather than sit as a nice-to-have technology.
In other words, Chrysos has both a structural growth story and a cyclical tailwind behind it. Structurally, miners and labs are adopting a better assay method. Cyclically, a stronger gold price should support more exploration, more development work and more sample throughput. That combination helps explain why the company has continued to build momentum with customers.
The pushback, of course, is valuation. The market is already factoring in continued strong deployment, rising sample volumes and further margin expansion. We like the business a lot, and the stronger gold backdrop only adds to the appeal, but it also means expectations are high and the room for execution missteps is smaller than it was a year ago. This valuation point is an inference based on the company’s current growth profile and how the market typically prices high-quality, recurring-revenue industrial technology businesses.
Overall, we believe the technology is genuinely differentiated, the customer wins are accelerating, and the unit economics at scale look attractive. It’s not cheap on traditional metrics, but the market is pricing a future where PhotonAssay becomes the industry standard, and the evidence so far suggests that’s a reasonable bet.
- The recent pullback from above $10 to ~$7 has improved the risk/reward materially, and we are now looking to add a position in the Emerging Companies Portfolio.
MM is bullish C79 ~$7.50
Add To Hit List
